UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

What is the recommended management for cardiac amyloidosis, including disease-modifying therapy for transthyretin (ATTR) and light-chain (AL) subtypes and supportive cardiac care?

Key Information
summary/abstract

Management of Cardiac Amyloidosis

For AL cardiac amyloidosis, initiate daratumumab-based chemotherapy (Dara-CyBorD) immediately as first-line therapy, while for ATTR cardiac amyloidosis, start tafamidis or acoramidis as disease-modifying therapy alongside aggressive diuresis for heart failure symptoms.


Disease-Modifying Therapy by Subtype

AL Amyloidosis: Plasma Cell-Directed Treatment

The primary goal is eradicating the clonal plasma cells producing toxic light chains. Daratumumab combined with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) is now the preferred first-line regimen 1external link, opens in a new tab. This has largely supplanted high-dose melphalan with autologous stem cell transplantation (HDM/SCT), though SCT remains an option for highly selected patients with low cardiac burden